Physician profile
Marcus A Button
NPI 1316943236
$3,447.72
in general payments reported to CMS, 2019-2025
41 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $268 · 2021: $683 · 2022: $370 · 2023: $791 · 2024: $569 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.55 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $342.64 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $323.98 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $254.44 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $217.72 | 2020-2024 | Ingrezza |
| Lilly USA, LLC | $206.80 | 2020-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $172.21 | 2019-2024 | Yupelri |
| Gilead Sciences, INC. | $134.47 | 2020-2025 | |
| Novo Nordisk INC | $125.68 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $124.44 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $72.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $69.74 | 2019 | |
| Nestle Healthcare Nutrition INC. | $68.67 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $66.60 | 2021-2025 | Rexulti |
| Grifols USA, LLC | $62.86 | 2024 | Prolastin-C Liquid |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $62.20 | 2020 | |
| Eisai INC. | $56.90 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $52.53 | 2024-2025 | Zenpep |
| Paratek Pharmaceuticals, INC. | $48.11 | 2024-2025 | Nuzyra, Xhance |
| Scilex Pharmaceuticals INC. | $47.66 | 2023-2024 | Ztlido |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.33 | 2022 | |
| Dexcom, INC. | $32.74 | 2024-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $32.16 | 2023-2024 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $30.50 | 2023-2024 | Breztri |
| Inogen, INC. | $30.22 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Insulet Corporation | $28.45 | 2024 | Omnipod |
| Sunovion Pharmaceuticals INC. | $28.04 | 2020 | |
| Baxter Healthcare | $26.73 | 2023 | Hillrom - Life 2000 Ventilation System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.35 | 2023 | Caplyta |
| Sanofi Pasteur INC. | $25.93 | 2022 | |
| Lucid Diagnostics INC. | $23.17 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $21.35 | 2022 | |
| Glaxosmithkline, LLC. | $20.85 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.89 | 2020 | |
| Philips North America LLC | $19.66 | 2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $18.22 | 2021 | |
| Sumitomo Pharma America, INC. | $18.15 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $17.90 | 2025 | Auvelity |
| Verona Pharma, INC. | $15.52 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $14.21 | 2025 | Yupelri |
| Exact Sciences Corporation | $13.29 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Button listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.